Call open for 2026 AbbVie Scandinavia Golden Ticket in partnership with KI Innovations

KI Innovations have partnered with AbbVie, a global biopharmaceutical company, to launch a Scandinavia Golden Ticket designed to accelerate companies developing novel, transformational therapies and innovations for immunology, oncology, neuroscience, eye care, aesthetics, or other specialities including obesity, GI and hepatology.

The Golden Ticket programme is designed to support innovative early-stage biotech companies in their efforts to accelerate the development of new therapies to improve human health. The programme offers the opportunity to secure one year of funding for lab space and mentorship and scientific expertise to support the company’s development.

Call opens December 1st.

Call closes January 31st

Critera to apply:

Are you an early-stage Life Science biotech Startup  and you meet the following AbbVie criteria – welcome to apply!

• Early-stage life science companies and biotech startups that are pursuing: 
  • Therapeutics (any modality) and life-science therapeutic platform technologies (e.g. Gene therapy, novel cell therapy, gene editing or novel drug discovery platform technologies, including AI- platforms for drug discovery).  
  • Therapeutic areas of interest: Immunology, Oncology, Neuroscience, Eye Care, Obesity, Medical Aesthetics 
  • Diagnostics, Devices, Research Tools, and Healthcare Services/IT are excluded. 
  • Companies must have their principal place of business in Sweden or be willing to relocate. 
  • Companies must not have a major partnership with another large biopharmaceutical company; however, current, or prior recipients of similar awards sponsored by other companies or lab spaces are eligible to apply. 
  • Total equity funding raised must be less than 7M Euros before application  
  • Companies must not have recurring sales revenue 
  • Companies must be in the life sciences and have an impact on human health 
  • Companies must be financially and scientifically ready to move into the incubator within two-nine months of receiving the Golden Ticket 
  • Companies must be eligible to receive state aid according to EU-regulation (Article 22 – GBER,
    and/or de minimis)

The Prize – The AbbVie Scandinavia Golden Ticket program offers one year of access to:

• Lab space, with access to research and office facilities and services for 1-2 scientists, provided by KI Innovations in Stockholm.
• Mentorship and business coaching from KI Innovations throughout the year.
• Tailored support from AbbVie’s international researchers and mentors.
• Exclusive access to AbbVie and KI Innovations networks during the year, with the opportunity for future collaboration.

Apply:

Fill in this application form, AND send your slide deck to goldenticket@kiinnovations.se by January 31st.

Applicants must provide a non-confidential slide deck of no more than ten slides that emphasize:

• Your company’s mission

• Management team & expertise

• The science behind technology or asset

• The prioritized and potentially applicable indications

• Differentiation point: What makes your technology different from the competitors?

• Relevant IP and publications that include data supporting your science

• Mitigation of Risk: What are the potential pitfalls and key challenges

• Anticipated benefits of securing an AbbVie – Golden Ticket. Anticipated move in date to selected facility & company roadmap and upcoming key milestones (including financing)
• Roadmap and growth plan for the timeframe of the Golden Ticket award
• PDF format

We thank you in advance for your application!